Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RGNX |
---|---|---|
09:32 ET | 9391 | 10.88 |
09:36 ET | 1111 | 10.81 |
09:38 ET | 200 | 10.77 |
09:43 ET | 600 | 10.79 |
09:45 ET | 500 | 10.78 |
09:50 ET | 100 | 10.78 |
09:52 ET | 100 | 10.71 |
09:54 ET | 417 | 10.71 |
09:56 ET | 2570 | 10.73 |
09:59 ET | 1000 | 10.65 |
10:01 ET | 2712 | 10.59 |
10:03 ET | 1000 | 10.62 |
10:10 ET | 940 | 10.5738 |
10:12 ET | 1255 | 10.53 |
10:14 ET | 1226 | 10.6 |
10:15 ET | 400 | 10.57 |
10:17 ET | 200 | 10.56 |
10:19 ET | 2090 | 10.65 |
10:26 ET | 300 | 10.62 |
10:28 ET | 100 | 10.6 |
10:30 ET | 2616 | 10.645 |
10:32 ET | 1900 | 10.615 |
10:33 ET | 2152 | 10.64 |
10:35 ET | 300 | 10.62 |
10:37 ET | 952 | 10.58 |
10:39 ET | 730 | 10.62 |
10:44 ET | 300 | 10.64 |
10:48 ET | 1233 | 10.655 |
10:50 ET | 1050 | 10.7 |
10:55 ET | 3562 | 10.705 |
11:00 ET | 300 | 10.68 |
11:02 ET | 100 | 10.68 |
11:06 ET | 820 | 10.63 |
11:08 ET | 400 | 10.68 |
11:09 ET | 450 | 10.66 |
11:11 ET | 325 | 10.64 |
11:13 ET | 125 | 10.65 |
11:18 ET | 600 | 10.665 |
11:22 ET | 100 | 10.65 |
11:26 ET | 200 | 10.635 |
11:29 ET | 1724 | 10.62 |
11:31 ET | 700 | 10.6 |
11:42 ET | 200 | 10.57 |
11:44 ET | 2742 | 10.57 |
11:45 ET | 200 | 10.62 |
11:47 ET | 1526 | 10.6272 |
11:49 ET | 685 | 10.65 |
11:51 ET | 405 | 10.61 |
11:54 ET | 100 | 10.61 |
11:56 ET | 322 | 10.61 |
11:58 ET | 980 | 10.59 |
12:00 ET | 800 | 10.56 |
12:02 ET | 1759 | 10.57 |
12:03 ET | 100 | 10.57 |
12:05 ET | 600 | 10.55 |
12:07 ET | 330 | 10.56 |
12:12 ET | 100 | 10.55 |
12:14 ET | 261 | 10.545 |
12:16 ET | 250 | 10.53 |
12:20 ET | 5536 | 10.57 |
12:21 ET | 468 | 10.58 |
12:23 ET | 956 | 10.5878 |
12:25 ET | 324 | 10.58 |
12:27 ET | 900 | 10.58 |
12:30 ET | 2351 | 10.64 |
12:32 ET | 677 | 10.64 |
12:34 ET | 1407 | 10.62 |
12:36 ET | 100 | 10.63 |
12:38 ET | 100 | 10.63 |
12:39 ET | 100 | 10.62 |
12:41 ET | 579 | 10.63 |
12:43 ET | 300 | 10.6 |
12:45 ET | 100 | 10.6 |
12:48 ET | 200 | 10.59 |
12:50 ET | 454 | 10.59 |
12:52 ET | 100 | 10.6 |
12:54 ET | 300 | 10.59 |
12:56 ET | 100 | 10.6 |
12:57 ET | 100 | 10.59 |
12:59 ET | 1249 | 10.62 |
01:01 ET | 500 | 10.64 |
01:03 ET | 100 | 10.61 |
01:06 ET | 100 | 10.6 |
01:08 ET | 100 | 10.57 |
01:10 ET | 100 | 10.563 |
01:12 ET | 200 | 10.59 |
01:14 ET | 1952 | 10.58 |
01:15 ET | 100 | 10.59 |
01:17 ET | 100 | 10.59 |
01:19 ET | 1192 | 10.6 |
01:21 ET | 3190 | 10.68 |
01:24 ET | 200 | 10.67 |
01:26 ET | 200 | 10.7 |
01:28 ET | 700 | 10.68 |
01:30 ET | 200 | 10.675 |
01:32 ET | 200 | 10.69 |
01:33 ET | 100 | 10.67 |
01:37 ET | 1200 | 10.73 |
01:39 ET | 400 | 10.74 |
01:42 ET | 1500 | 10.73 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Regenxbio Inc | 532.9M | -1.8x | --- |
Y-mAbs Therapeutics Inc | 499.4M | -22.6x | --- |
SAGE Therapeutics Inc | 639.1M | -1.3x | --- |
Urogen Pharma Ltd | 618.0M | -4.6x | --- |
Grail Inc | 411.3M | -0.3x | --- |
Alector Inc | 425.1M | -3.1x | --- |
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $532.9M |
---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.